The Genitourinary Cancer Management Group at the NYU Cancer Institute is committed to delivering state-of-the-art care from diagnosis through treatment for patients with all stages of genitourinary malignancies, including prostate, bladder, kidney, and testicular cancers; to translating scientific advances in medical knowledge into personalized, novel approaches with potential direct benefit for patients; and to being compassionate and attentive to the emotional needs of patients and their families.
Delivering State-of-the-Art, Evidence-Based Care: We recognize that the optimal care of patients with genitourinary malignancies requires a comprehensive multidisciplinary team approach that can only be delivered by expert healthcare providers. Therefore, the NYUCI has brought together an outstanding group of renowned uro-oncology specialists, including urologists, medical oncologists, and radiation therapists, who dedicate themselves full-time to the research, development, and implementation of innovative treatments for genitourinary cancer. Working together with specialized nurses and assistants, they use established as well as investigational approaches to tailor personalized treatments for patients while preserving quality of life.
A Tradition of Care: The NYU Cancer Institute builds on an exemplary tradition of care initiated in 1877 by NYU physicians at Bellevue Hospital who founded the first Department of Urology in the United States. A century later, the Department of Urology stands high in academic ranking and among patients in New York and around the country. This outstanding and dynamic team of urologic surgeons excels in the diagnosis, prevention, and primary treatment of all genitourinary malignancies.
The NYU Cancer Institute has further enhanced this tradition of excellence by committing a large amount of resources to bolster the Medical Oncology Genitourinary Program, with the recruitment of experienced physician-scientists and clinicians who are focused on developing new therapies for patients with high-risk, recurrent, or advanced genitourinary cancers. In the same breadth, it has supported the Radiation Therapy Program's efforts, to improve upon this primary treatment for genitourinary cancers.
Translating Scientific Advances into Novel Treatments: To propel the NYU Cancer Institute to the forefront of genitourinary cancer care, we have a made a commitment to translating scientific advances into novel treatments with the potential to directly benefit patients affected with these diseases. Our team of uro-oncologists is actively engaged in research and works closely with basic scientists to elucidate the molecular basis of urologic malignancies and to devise novel therapies. This knowledge is incorporated into clinical trials with the potential to improve upon existing treatments for each stage of disease.
We utilize a wide array of agents, including specific molecular targeted therapies and new chemotherapy drugs, vaccines, and even novel hormonal approaches to avoid androgen deprivation. Our investigators are also working on new diagnostic approaches and examination of risk factors, as well as identifying stem cells that give rise to prostate cancer.
Support and Compassion: We are highly aware of the effects of cancer on the mind and spirit of patients and their loved ones. Thus, the NYUCI hosts one of the best known support groups for prostate cancer. Man to Man® is an interactive, highly attended support group that meets on a monthly basis. It offers both education and peer support for men with prostate cancer in all stages of the disease. In addition, we have psychosocial services and nutritionists to assist patients with other genitourinary cancers and their families.
Whether you are seeking a second opinion or are ready to start treatment, we encourage you to consult with our team of genitourinary cancer specialists to learn more details about your diagnostic and treatment options and help you make the best informed decision about your care.